Once the diagnosis of CIS or MS is made, treatment
can be considered. DMTs, available since the early
1990s, are able to alter the natural history of RRMS
because of their anti-inflammatory effect on the immune
system. These agents have shown efficacy in the
reduction of relapse frequency and reduction in CNS
inflammation and have a variable ability to reduce
the progression of disability. Emerging treatments in
the research pipeline promise alternate mechanisms of
action from the currently approved treatments as well
as efficacy in relapse reduction, inflammatory events,
and progression of disability